Ingredient name record

Palmitoyl Pentapeptide-4

Evidence at a glance

1official function labelsIngredient context 1selected human studiesNot a full review

0selected legal receiptsNot a compliance verdict

Evidence coverage, not an efficacy or safety score.

Identity & coverage details

Official CosIng inventory context recorded; chemical identity and the complete current regulatory profile remain unverified; selected human studies available.

Recorded presence is not a safety rating, recommended dose or benefit claim.

Identity and formulation context

Names are indexed using case and whitespace normalization. Botanical, chemical and marketing identities have not been independently equated.

This selected study names Palmitoyl Pentapeptide-4 separately from Acetylhexapeptide-3. Results are not transferred to Acetyl Hexapeptide-8, another peptide or a marketed peptide complex.

Functions listed by CosIng

SKIN CONDITIONING - MISCELLANEOUS

Inventory functions describe the ingredient entry, not a finished product’s effects.

How this inventory match is used

The European Commission’s CosIng inventory is informational. An entry is not permission to use an ingredient or a safety assessment. Listed functions describe the inventory entry; they do not establish a finished product’s effects. The match uses the exact ingredient name, with case and whitespace normalization.

PALMITOYL PENTAPEPTIDE-4 · Inventory identifiers

Inventory record: 56913 · Active
CAS identifiers in this entry: 521091-64-5/ 214047-00-4
EC identifiers in this entry: -/ -

Checked 2026-10-02 · Read the official CosIng entry

Human study context

Primary publications checked 2026-10-03. These are selected studies, not a systematic review, safety rating or instructions for using a product.

Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet.

2023 · Original abstract reviewed

Material tested: Palmitoyl pentapeptide-4 cream versus Acetylhexapeptide-3 cream and placebo; concentrations absent from the abstract.
Study design: Double-blind randomized three-group trial.
Participants: 21 Indonesian women aged 26–55.
Concentration and schedule in the study: Periorbital application twice daily for eight weeks.
What the authors reported: Authors reported improvements in some participants and results favoring the palmitoyl peptide on photographs, measurements and questionnaires.

What this does not establish

Small initial study; numerical effect sizes and concentrations absent.
The authors request a larger, longer trial; no universal wrinkle or safety claim follows.

Read the original publication

Still unverified

Selected primary abstracts only, not a systematic review or a complete scientific profile.
Test preparations have not been matched to any Treatfolio product, market, batch or package.
Study schedules are not consumer instructions; regulatory status and personal suitability require separate evidence.
Chemical identity, the complete current regulatory profile and finished-product effects remain unverified.